Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Oncotargets and Therapy
|
September 19, 2017
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
Ben C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Sarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Molecular Cancer Therapeutics
|
April 24, 2024
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, et al.
Cancer Immunology, Immunotherapy : CII
|
July 9, 2017
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Robert Wesolowski, Megan C Duggan, Andrew Stiff, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Oncotargets and Therapy
|
October 13, 2016
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
Joseph Markowitz, Zachary Abrams, Naduparambil K Jacob, et al.
Journal for Immunotherapy of Cancer
|
January 14, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial
Andrew S Brohl, Vernon K Sondak, Evan J Wuthrick, et al.
Research Square
|
August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimation
Alyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
NPJ Precision Oncology
|
January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimation
Alyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> <sup>V600E</sup>-Mutant Melanoma
Zeynep Eroglu, Y Ann Chen, Geoffrey T Gibney, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Oncotargets and Therapy
|
September 19, 2017
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
Ben C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Sarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Molecular Cancer Therapeutics
|
April 24, 2024
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, et al.
Cancer Immunology, Immunotherapy : CII
|
July 9, 2017
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Robert Wesolowski, Megan C Duggan, Andrew Stiff, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Oncotargets and Therapy
|
October 13, 2016
MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches
Joseph Markowitz, Zachary Abrams, Naduparambil K Jacob, et al.
Journal for Immunotherapy of Cancer
|
January 14, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial
Andrew S Brohl, Vernon K Sondak, Evan J Wuthrick, et al.
Research Square
|
August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimation
Alyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
NPJ Precision Oncology
|
January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimation
Alyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2018
Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> <sup>V600E</sup>-Mutant Melanoma
Zeynep Eroglu, Y Ann Chen, Geoffrey T Gibney, et al.
Page
of 9